These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 21537871)

  • 21. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
    Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
    Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRAF mutation, selected miRNAs and genes expression in primary papillary thyroid carcinomas and local lymph node metastases.
    Kalfert D; Ludvikova M; Pesta M; Hakala T; Dostalova L; Grundmannova H; Windrichova J; Houfkova K; Knizkova T; Ludvik J; Polivka J; Kholova I
    Pathol Res Pract; 2024 Jun; 258():155319. PubMed ID: 38696857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In Situ Hybridization Analysis of miR-146b-5p and miR-21 in Thyroid Nodules: Diagnostic Implications.
    Guo Z; Hardin H; Montemayor-Garcia C; Asioli S; Righi A; Maletta F; Sapino A; Lloyd RV
    Endocr Pathol; 2015 May; 26(2):157-63. PubMed ID: 25771986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New global analysis of the microRNA transcriptome of primary tumors and lymph node metastases of papillary thyroid cancer.
    Saiselet M; Gacquer D; Spinette A; Craciun L; Decaussin-Petrucci M; Andry G; Detours V; Maenhaut C
    BMC Genomics; 2015 Oct; 16():828. PubMed ID: 26487287
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of correlation between BRAF V600E mutational status and the expression profile of a distinct set of miRNAs in papillary thyroid carcinoma.
    Sheu SY; Grabellus F; Schwertheim S; Handke S; Worm K; Schmid KW
    Horm Metab Res; 2009 Jun; 41(6):482-7. PubMed ID: 19370505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Down-regulation of 14q32-encoded miRNAs and tumor suppressor role for miR-654-3p in papillary thyroid cancer.
    Geraldo MV; Nakaya HI; Kimura ET
    Oncotarget; 2017 Feb; 8(6):9597-9607. PubMed ID: 28030816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNA Profiling in Papillary Thyroid Cancer.
    Armos R; Bojtor B; Papp M; Illyes I; Lengyel B; Kiss A; Szili B; Tobias B; Balla B; Piko H; Illes A; Putz Z; Kiss A; Toth E; Takacs I; Kosa JP; Lakatos P
    Int J Mol Sci; 2024 Aug; 25(17):. PubMed ID: 39273308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overexpression of miR-221 is associated with aggressive clinicopathologic characteristics and the BRAF mutation in papillary thyroid carcinomas.
    Zhou YL; Liu C; Dai XX; Zhang XH; Wang OC
    Med Oncol; 2012 Dec; 29(5):3360-6. PubMed ID: 22855362
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRAF
    Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J
    World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNA Expression and Association with Clinicopathologic Features in Papillary Thyroid Cancer: A Systematic Review.
    Aragon Han P; Weng CH; Khawaja HT; Nagarajan N; Schneider EB; Umbricht CB; Witwer KW; Zeiger MA
    Thyroid; 2015 Dec; 25(12):1322-9. PubMed ID: 26414548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
    Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
    Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma.
    Minna E; Romeo P; Dugo M; De Cecco L; Todoerti K; Pilotti S; Perrone F; Seregni E; Agnelli L; Neri A; Greco A; Borrello MG
    Oncotarget; 2016 Mar; 7(11):12731-47. PubMed ID: 26871295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012.
    Albarel F; Conte-Devolx B; Oliver C
    Ann Endocrinol (Paris); 2012 Jun; 73(3):155-64. PubMed ID: 22503804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Associations of miR-146a and miR-146b expression and clinical characteristics in papillary thyroid carcinoma.
    Sun M; Fang S; Li W; Li C; Wang L; Wang F; Wang Y
    Cancer Biomark; 2015; 15(1):33-40. PubMed ID: 25524940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression profile and clinical significance of microRNAs in papillary thyroid carcinoma.
    Peng Y; Li C; Luo DC; Ding JW; Zhang W; Pan G
    Molecules; 2014 Aug; 19(8):11586-99. PubMed ID: 25100252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature.
    Krishnamurthy A; Ramshankar V; Murherkar K; Vidyarani S; Raghunandhan GC; Das A; Desai PB; Albert K
    Indian J Cancer; 2017; 54(1):372-378. PubMed ID: 29199726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative genomic hybridization, BRAF, RAS, RET, and oligo-array analysis in aneuploid papillary thyroid carcinomas.
    Rodrigues R; Roque L; Espadinha C; Pinto A; Domingues R; Dinis J; Catarino A; Pereira T; Leite V
    Oncol Rep; 2007 Oct; 18(4):917-26. PubMed ID: 17786355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma.
    Chen YT; Kitabayashi N; Zhou XK; Fahey TJ; Scognamiglio T
    Mod Pathol; 2008 Sep; 21(9):1139-46. PubMed ID: 18587330
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of the novel tumor-suppressor gene CCDC67 in papillary thyroid carcinoma.
    Yin DT; Xu J; Lei M; Li H; Wang Y; Liu Z; Zhou Y; Xing M
    Oncotarget; 2016 Feb; 7(5):5830-41. PubMed ID: 26716505
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot.
    Musholt PB; Musholt TJ; Morgenstern SC; Worm K; Sheu SY; Schmid KW
    World J Surg; 2008 May; 32(5):722-8. PubMed ID: 18235983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.